Nymox Pharmaceutical Corporation NYMXF
OTC PK
| 12/31/2024 | 09/30/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| Net Income | -- | -- | -8.84M | ||
| Total Depreciation and Amortization | -- | -- | 169.00K | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -- | -- | 3.80M | ||
| Change in Net Operating Assets | -- | -- | 821.00K | ||
| Cash from Operations | -- | -- | -4.06M | ||
| Capital Expenditure | -- | -- | -3.00K | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -- | -- | -3.00K | ||
| Total Debt Issued | -- | -- | 1.75M | ||
| Total Debt Repaid | -- | -- | -173.00K | ||
| Issuance of Common Stock | -- | -- | 1.15M | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | -- | -- | 2.73M | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -- | -- | -1.33M | ||